Maggie C Walter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6037864/publications.pdf

Version: 2024-02-01

51 papers	1,440 citations	394421 19 h-index	345221 36 g-index
52 all docs	52 docs citations	52 times ranked	2240 citing authors

#	Article	IF	Citations
1	Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 â€“ A Prospective Observational Study. Journal of Neuromuscular Diseases, 2019, 6, 453-465.	2.6	132
2	Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. Journal of Neuromuscular Diseases, 2017, 4, 293-306.	2.6	125
3	Disease burden of spinal muscular atrophy in Germany. Orphanet Journal of Rare Diseases, 2016, 11, 58.	2.7	84
4	Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1071-1081.	1.9	81
5	Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet Journal of Rare Diseases, 2013, 8, 26.	2.7	77
6	SMArtCAREÂ-ÂA platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2019, 14, 18.	2.7	67
7	Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology, 2016, 87, 295-298.	1.1	60
8	Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy. Scientific Reports, 2016, 6, 33362.	3.3	60
9	Creatine monohydrate in myotonic dystrophy. Journal of Neurology, 2002, 249, 1717-1722.	3.6	58
10	MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77.	1.9	55
11	50 years to diagnosis: Autosomal dominant tubular aggregate myopathy caused by a novel STIM1 mutation. Neuromuscular Disorders, 2015, 25, 577-584.	0.6	47
12	MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscular Disorders, 2019, 29, 827-841.	0.6	46
13	Variable reduction of caveolin-3 in patients with LGMD2B/MM. Journal of Neurology, 2003, 250, 1431-1438.	3.6	43
14	Late-onset ptosis and myopathy in a patient with a heterozygous insertion in POLG2. Journal of Neurology, 2010, 257, 1517-1523.	3.6	39
15	Deletion of the LMNA initiator codon leading to a neurogenic variant of autosomal dominant Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2005, 15, 40-44.	0.6	38
16	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017.	0.6	25
17	Recent developments in Duchenne muscular dystrophy: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 681-685.	7.3	25
18	Genome editing for Duchenne muscular dystrophy: a glimpse of the future?. Gene Therapy, 2021, 28, 542-548.	4.5	24

#	Article	IF	Citations
19	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcotâ€“Marieâ€“Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	2.7	23
20	De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany. Orphanet Journal of Rare Diseases, 2019, 14, 152.	2.7	22
21	Abnormal proliferation and spontaneous differentiation of myoblasts from a symptomatic female carrier of X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2015, 25, 127-136.	0.6	21
22	Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 941-952.	1.9	20
23	Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9. Annals of Clinical and Translational Neurology, 2020, 7, 757-766.	3.7	20
24	A scalable, clinically severe pig model for Duchenne muscular dystrophy. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	20
25	Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1224-1226.	1.9	19
26	The Variant p.(Arg183Trp) in SPTLC2 Causes Late-Onset Hereditary Sensory Neuropathy. NeuroMolecular Medicine, 2016, 18, 81-90.	3.4	18
27	Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease. Neuromuscular Disorders, 2021, 31, 265-280.	0.6	18
28	Cost of illness in Charcot-Marie-Tooth neuropathy. Neurology, 2019, 92, e2027-e2037.	1.1	17
29	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Annals of Neurology, 2021, 89, 967-978.	5.3	17
30	Laminopathy presenting as familial atrial fibrillation. International Journal of Cardiology, 2010, 145, 394-396.	1.7	16
31	Rare diagnosis of telethoninopathy (LGMD2G) in a Turkish patient. Neuromuscular Disorders, 2017, 27, 856-860.	0.6	15
32	Treatment for inclusion body myositis. The Cochrane Library, 0, , .	2.8	11
33	A new case of limb girdle muscular dystrophy 2G in a Greek patient, founder effect and review of the literature. Neuromuscular Disorders, 2018, 28, 532-537.	0.6	11
34	Charcot-Marie-Tooth disease type 2CC due to a frameshift mutation of the neurofilament heavy polypeptide gene in an Austrian family. Neuromuscular Disorders, 2019, 29, 392-397.	0.6	10
35	Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases, 2021, 8, 543-551.	2.6	9
36	Cardiac and pulmonary findings in dysferlinopathy: A 3â€year, longitudinal study. Muscle and Nerve, 2022, 65, 531-540.	2.2	9

#	Article	IF	Citations
37	Tasks and interfaces in primary and specialized palliative care for Duchenne muscular dystrophy â€“ A patientsâ€™ perspective. Neuromuscular Disorders, 2020, 30, 975-985.	0.6	8
38	The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. Acta Myologica, 2017, 36, 203-206.	1.5	8
39	Long-term follow-up in patients with CCFDN syndrome. Neurology, 2014, 83, 1337-1344.	1.1	6
40	Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles. Histochemistry and Cell Biology, 2016, 146, 569-584.	1.7	6
41	Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. Acta Myologica, 2020, 39, 2-12.	1.5	5
42	Novel approaches to treat muscular dystrophies. Expert Opinion on Investigational Drugs, 2001, 10, 695-707.	4.1	4
43	Health-related Quality of Life and Satisfaction with German Health Care Services in Patients with Charcot-Marie-Tooth Neuropathy. Journal of Neuromuscular Diseases, 2022, 9, 211-220.	2.6	4
44	Congenital myopathy and epidermolysis bullosa due to PLEC variant. Neuromuscular Disorders, 2021, 31, 1212-1217.	0.6	4
45	Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology, 2022, 13, 828525.	2.4	4
46	Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3. Journal of Neuromuscular Diseases, 2021, 8, 537-542.	2.6	3
47	Intensive Teenage Activity Is Associated With Greater Muscle Hyperintensity on T1W Magnetic Resonance Imaging in Adults With Dysferlinopathy. Frontiers in Neurology, 2020, 11, 613446.	2.4	3
48	Slowly Progressive Limb-Girdle Weakness and HyperCKemia â€“ Limb Girdle Muscular Dystrophy or Anti-3-Hydroxy-3-Methylglutaryl-CoA-Reductase-Myopathy?. Journal of Neuromuscular Diseases, 2022, , 1-8.	2.6	2
49	Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study. Journal of Medical Economics, 2022, 25, 808-816.	2.1	1
50	FV 880. Disorders of Coagulation in Duchenne Muscular Dystrophy?â€”Results of a Registry-Based Online Questionnaire. Neuropediatrics, 2018, 49, .	0.6	0
51	SMArtCARE Real-World Data on Drug Treatment for Spinal Muscular Atrophy. , 2021, 52, .		0